Effect of gliclazide on diabetic complications: Comparison to glibenclamide by retrospective analysis

Yumiko Takizawa, Jo Satoh, Kazuma Takahashi, Hisamitsu Ishihara, Masashi Hirai, Hideki Katagiri, Yoshinori Hinokio, Susumu Suzuki, Yoshitomo Oka

Research output: Contribution to journalArticlepeer-review


Because gliclazide (GCZ), a sulfonylurea with various bioactivities, in addition to insulin-secretagogue activity, including free-radical scavenging, may suppress the development of diabetic microangiopathy, we retrospectively compared the duration from diabetes onset until diagnosis of retinopathy and nephropathy between patients treated with GCZ and those treated with glibenclamide (GBC) as a control by the Kaplan-Meier method and Cox's proportional hazard analysis. The duration from onset until diagnosis of retinopathy was significantly longer in the GCZ group. Independent variables affecting prognosis were lower HbA1c and BMI in the GCZ group but not GCZ or GBC per se. Although the period until diagnosis of microalbuminuria or proteinuria did not differ between groups, proteinuria in patients with diabetes duration of more than 25 years tended to be less frequent in the GCZ group. This study confirmed the preventive effect of good glycemic control on diabetic retinopathy and indicated a relationship between BMI and retinopathy.

Original languageEnglish
Pages (from-to)283-289
Number of pages7
JournalJournal of the Japan Diabetes Society
Issue number4
Publication statusPublished - 2004 Jun 3
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Effect of gliclazide on diabetic complications: Comparison to glibenclamide by retrospective analysis'. Together they form a unique fingerprint.

Cite this